Thursday, October 6, 2022
HomeHealthThai king's medical firm reports record profit after vaccine deal with AstraZeneca...

Thai king's medical firm reports record profit after vaccine deal with AstraZeneca – Reuters

The signage of Siam Bioscience factory, where the vaccine against the coronavirus disease (COVID-19) will be produced, is pictured outside Bangkok, Thailand June 3, 2021. REUTERS/Soe Zeya Tun
BANGKOK, Aug 25 (Reuters) – Thai drugmaker Siam Bioscience, owned by the country's king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc's (AZN.L) COVID-19 vaccine, government data shows.
The company is part of King Maha Vajiralongkorn's vast fortune, which includes land and property estimated at between $30 billion and $60 billion.
Founded in 2009 by the late King Bhumibol Adulyadej to produce biopharmaceuticals and improve public health, the company had since been loss-making and reported its first profit only in 2020 of 35.7 million baht ($995,000).
Its business improved sharply last year, as it began manufacturing vaccines for the first time.
Profit soared a whopping 4,650% to 1.69 billion baht and revenues increased by 1,500% to a record 4.9 billion baht, aided by its contract to manufacture 200 million doses of the Anglo-Swedish firm's COVID-19 vaccine.
The deal came under fire from a prominent Thai opposition politician who questioned why the contract went to a company that was owned by the king and had never made vaccines before.
He now faces up to 20 years in prison following his indictment earlier this year for insulting the king and violating a cyber law. read more
Thailand's health officials have defended the decision, while AstraZeneca has said that Siam Bioscience had passed the same quality and capacity checks it conducts on its more than 20 licensed manufacturers worldwide.
Siam Bioscience's headquarters has also become a site for anti-government protesters, with some demanding reform of the monarchy.
The company received a 600 million baht government subsidy to develop its production capacity and has said it would manufacture vaccines under a "no profit, no loss" policy, meaning it would sell the vaccines at cost.
($1 = 35.8800 baht)
Our Standards: The Thomson Reuters Trust Principles.
Cancer detection test maker Grail, acquired by Illumina Inc last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri test through a new agreement with life insurer John Hancock, a division of Manulife Financial .
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments